Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

488.36 -0.22 (-0.05%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Madrigal Pharmaceuticals (NASDAQ:MDGL) Q3 2025 Earnings: Revenue Beat and EPS Miss Drive Pre-Market Surge
Madrigal's Q3 2025 earnings show Rezdiffra sales of $287.3M, crushing estimates. With over 29,500 patients on therapy, the stock surged on strong commercial uptake. 
Via Chartmill
Earnings Scheduled For November 4, 2025
 
Via Benzinga
A Look Ahead: Madrigal Pharmaceuticals's Earnings Forecast
 
Via Benzinga
Beyond The Numbers: 10 Analysts Discuss Madrigal Pharmaceuticals Stock
 
Via Benzinga
6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year. 
Via Benzinga
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 7 Analysts
In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and bearish perspectives. 
Via Benzinga
MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) Screens as High-Growth Momentum Stock Meeting Minervini Trend Template
Madrigal Pharmaceuticals (MDGL) meets Mark Minervini's high-growth trend template, showing explosive revenue growth and a perfect 10/10 technical rating. 
Via Chartmill
MarketBeat Week in Review – 09/08 - 09/12
Markets had another strong week as inflaton data set the stage for the Federal Reserve’s meeting next week; a rate cut is expected but may already be priced in 
Via MarketBeat
Topics Economy
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 6 Analysts
 
Via Benzinga
CoreWeave and Madrigal's Insider Trades Flash Bullish Signals
Insider trades at NVIDIA-backed CoreWeave and Madrigal Pharmaceuticals are bullish indicators, but for very different reasons. 
Via MarketBeat
Topics Artificial Intelligence
Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure
Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment. 
Via Investor's Business Daily
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker
HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fibrosis treatment pipeline. 
Via Benzinga
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
Corporate Wins: Intel, Palo Alto Networks, and Novo Nordisk Drive Market Optimism
In a week marked by a surge of positive corporate news, three industry giants—Intel, Palo Alto Networks, and Novo Nordisk—have delivered significant boosts to investor confidence, signaling robust... 
Via MarketMinute
Topics Artificial Intelligence Economy
Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma
The FDA will allow patients with MASH to undergo Wegovy treatment, hampering the only other company with an approved MASH drug. 
Via Investor's Business Daily
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth. 
Via Benzinga
Billionaire Investor Buys Google And This Gold Miner Stock
John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet. 
Via Benzinga
Madrigal (MDGL) Q2 Revenue Soars 1,313%
Via The Motley Fool
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Beats Q2 2025 Revenue Estimates and Narrows Losses on Strong Rezdiffra Sales
Madrigal Pharmaceuticals (MDGL) beats Q2 2025 revenue estimates with $212.8M, driven by strong Rezdiffra sales, narrowing losses. Stock rises 12.8% pre-market. 
Via Chartmill
European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug
Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August. 
Via Benzinga
5 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Via The Motley Fool
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock
Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment,... 
Via Stocktwits
Topics Death
Uncovering Potential: Madrigal Pharmaceuticals's Earnings Preview
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.